Degradation of omeprazole induced by enteric polymer solutions and aqueous dispersions: HPLC investigations

Drug Development and Industrial Pharmacy

Volumn 31, Issue 2, 2005, Pages 151-160

  Riedel, A ^a   Leopold, C S ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Enteric coating polymers; HPLC; Kinetics; Omeprazole; pKa values

Indexed keywords

EUDRAGIT; OMEPRAZOLE; PHTHALIC ACID DERIVATIVE; POLYMER; PROTON PUMP INHIBITOR;

ACIDITY; AQUEOUS SOLUTION; ARTICLE; CORRELATION ANALYSIS; DEGRADATION KINETICS; DISPERSION; DRUG STABILITY; DRUG STRUCTURE; ENTERIC COATED TABLET; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; PH; PKA;

ANTI-ULCER AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; KINETICS; OMEPRAZOLE; POLYMERS; SOLUBILITY; SOLVENTS; TABLETS, ENTERIC-COATED;

EID: 14644444572     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-200047787     Document Type: Article

References (26)

1. Bodmeier, R., & Chen, H. (1991). Determination of the acidic degradation products, acetic, propionic, butyric, and phthalic acid in aqueous pseudolatexes of cellulosic esters by high performance liquid chromatography. Drug Development and Industrial Pharmacy, 17:1811-1822.
2. Bränström, A., Lindberg, P., Bergman, N.-K., Alminger, T., & Junggren, U. C. (1989). Chemical reactions of omeprazole and omeprazole analogues. I. A survey of the chemical transformation of omeprazole and its analogues. Acta Chemica Scandinavica, 43:536-548.
3. Chambliss, W. G. (1987). The forgotten dosage form: enteric coating tablets. Pharmaceutical Technology, 7:124-140.
4. Chen, C.-M., Chou, J., & Weng, T. Omeprazole Formulation. US Patent 6,096,340, Nov. 14, 1997.
5. Clissold, S. P., & Campoli-Richards, D. M. (1986). Omeprazole - a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs, 32:15-47.
6. Davidson, A. G., & McCallum, A. (1996). A survey of the stability of omeprazole products from 13 countries. Drug Development and Industrial Pharmacy, 22:1173-1185.
7. Davis, M. B. (1986). Preparation and stability of aqueous-based enteric polymer dispersions. Drug Development and Industrial Pharmacy, 12:1419-1448.
8. Ekpe, A., & Jacobsen, T. (1999). Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography. Drug Development and Industrial Pharmacy, 25:1057-1065.
9. Erickson, M., & Josefson, L. Pharmaceutical Formulation of Omeprazole. US Patent 6,090,827, May 18, 1998.
10. Gordon, M. S., Fratis, A., Goldblum, R., Jung, D., Schwartz, K. E., & Chowhan, Z. T. (1995). In vivo and in vitro evaluation of four different aqueous polymeric dispersions for producing an enteric coated tablet. International Journal of Pharmaceutics, 115:29-34.
11. Goskonda, S. R., & Lee, J. C. (2000). Hydroxypropyl methylcellulose phthalate. In: Kibbe, A. H., (Ed.). Handbook of Pharmaceutical Excipients (3rd ed.). Washington: American Pharmaceutical Association, pp. 256-260.
12. Hamdan, I. I. (2001). In vitro study of the interaction between omeprazole and the metal ions Zn(II), Cu(II), and Co(II). Pharmazie, 56:877-881.
13. Lagerström, P.-O., & Persson, B.-A. (1984). Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. Journal of Chromatography Biomedical Applications, 309:347-356.
14. Lee, F.-Y., Chen, S.-C., & Kuo, H.-C. Orally Administered Pharmaceutical Formulations of Benzimidazole Derivatives and the Method of Preparing the Same. US Patent 6,228,400 B1, Jan. 19, 2000.
15. Lövgren, K. I., Pilbrant, A. G., Yasumura, M., Morigaki, S., Oda, M., & Ohishi, N. New Pharmaceutical Preparation for Oral Use. EP Patent 0 2479 83 B 1, Apr. 16, 1987.
16. Lundberg, P. J., & Lövgren, K. New Pharmaceutical Formulation and Process. WO Patent 96/24338, Feb. 9, 1996.
17. Mathew, M., Das Gupta, V., & Bailey, R. E. (1995). Stability of omeprazole solutions at various pH values as determined by high-performance liquid chromatography. Drug Development and Industrial Pharmacy, 21:965-971.
18. Münzel, K., Büchi, J., & Schultz, D.-E. (1959). 6. Übung: Demineralisiertes und destilliertes Wasser. In: Galenisches Praktikum. Wissenschaftliche Verlagsgesellschaft mbH: Stuttgart, p. 196.
19. Parke, T. V., & Davis, W. W. (1954). Use of apparent dissociation constants in qualitative organic analysis. Analytical Chemistry, 26:642-645.
20. Persson, B.-A., Lagerström, P.-O., & Grundevik, I. (1985). Determination of omeprazole and metabolites in plasma and urine. Scandinavian Journal of Gastroenterology, 20:71-77.
21. Pilbrant, A. (1985). Development of an oral formulation of omeprazole. Scandinavian Journal of Gastroenterology, 20:113-119.
22. Quercia, R. A., Fan, C., Liu, X., & Chow, M. S. S. (1997). Stability of omeprazole in an extemporaneously prepared oral liquid. American Journal of Health-System Pharmacy, 54:1833-1836.
23. Ruiz, M. A., Reyes, I., Parera, A., & Gallardo, V. (2000). Adsorption of omeprazole on latex particles and characterization of the complex. II Farmaco, 55:314-318.
24. Schmidt-Mende, T. (2001). Freisetzung aus Magensaftresistent Überzogenen Arzneiformen. Düsseldorf: Heinrich-Heine-Universität.
25. +)-ATPase inhibiting 2-[(2-Pyridylmethyl)sulfinyl]benzimidazoles. 2. The reaction cascade induced by treatment with acids. Formation of 5H-Pyrido[1′,2′:4,5][1,2,4]thiadiazono[2,3-a]benzimidazol-13-ium salts and their reaction with thiols. Journal of Organic Chemistry, 52:4582-4592.
26. Storpirtis, S., & Rodrigues, D. (1998). In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets. Drug Development and Industrial Pharmacy, 24:1101-1107.